Achieve Life Sciences Inc (NASDAQ:ACHV) — Market Cap & Net Worth
Market Cap & Net Worth: Achieve Life Sciences Inc (ACHV)
Achieve Life Sciences Inc (NASDAQ:ACHV) has a market capitalization of $523.56 Million ($523.56 Million) as of June 23, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12105 globally and #2982 in its home market, demonstrating a -7.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Achieve Life Sciences Inc's stock price $5.10 by its total outstanding shares 102659057 (102.66 Million). Review how much debt does Achieve Life Sciences Inc carry to assess the company's total debt and financial obligations.
Achieve Life Sciences Inc Market Cap History: 2015 to 2026
Achieve Life Sciences Inc's market capitalization history from 2015 to 2026. Data shows change from $273.28 Billion to $523.56 Million (-47.56% CAGR).
Index Memberships
Achieve Life Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.02% | #325 of 976 |
|
NASDAQ Composite
IXIC
|
$40.53 Trillion | 0.00% | #1181 of 3165 |
Weight: Achieve Life Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Achieve Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Achieve Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
22303.91x
Achieve Life Sciences Inc's market cap is 22303.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $112.90 Billion | $5.06 Million | -$20.13 Million | 22303.91x | N/A |
Competitor Companies of ACHV by Market Capitalization
Companies near Achieve Life Sciences Inc in the global market cap rankings as of June 23, 2026.
Key companies related to Achieve Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $63.10 Billion USD.
- UCB SA (BR:UCB): Ranked #546 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $466.79 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.10 Billion | $612.50 |
| #546 | UCB SA | BR:UCB | $49.68 Billion | €247.60 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €796.00 |
Achieve Life Sciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Achieve Life Sciences Inc's market cap moved from $273.28 Billion to $ 523.56 Million, with a yearly change of -47.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $523.56 Million | +2.62% |
| 2025 | $510.22 Million | +41.19% |
| 2024 | $361.36 Million | -14.56% |
| 2023 | $422.96 Million | +68.16% |
| 2022 | $251.51 Million | -68.51% |
| 2021 | $798.69 Million | -3.95% |
| 2020 | $831.54 Million | -23.57% |
| 2019 | $1.09 Billion | -56.21% |
| 2018 | $2.48 Billion | -90.99% |
| 2017 | $27.58 Billion | -75.57% |
| 2016 | $112.90 Billion | -58.69% |
| 2015 | $273.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 23rd, 2026 the market cap of Achieve Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $523.56 Million USD |
| MoneyControl | $523.56 Million USD |
| MarketWatch | $523.56 Million USD |
| marketcap.company | $523.56 Million USD |
| Reuters | $523.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more